Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, double-simulated, and positive-drug parallel-controlled Phase III clinical study to evaluate the effectiveness and safety of H008 tablets in patients with duodenal ulcer

Next Previous
Trial Profile

A multi-center, randomized, double-blind, double-simulated, and positive-drug parallel-controlled Phase III clinical study to evaluate the effectiveness and safety of H008 tablets in patients with duodenal ulcer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Keverprazan (Primary) ; Lansoprazole (Primary)
  • Indications Duodenal ulcer
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Carephar Pharmaceutical

Most Recent Events

  • 15 Feb 2023 According to a Jiangsu Ke Feiping Pharmaceutical media release, the State Drug Administration approved the marketing of Caprasyn Hydrochloride Tablets for the treatment of duodenal ulcer and reflux esophagitis.
  • 11 Oct 2022 Primary endpoint (Duodenal-ulcer healing rate at 6 weeks) has been met, as per results presented at the 30th United European Gastroenterology Week.
  • 11 Oct 2022 Results assessing the efficacy and safety of keverprazan (H008) in the treatment of duodenal ulcer, presented at the 30th United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top